Sign inJoin waitlistJoin the waitlist

Allison Bock

Assistant Professor · Univ of Utah Sch of Med

Credentials: · · · · · ·

History

Univ of Utah Sch of Med · Huntsman Cancer Institute & Hospital
Present

Hematology and Medical Oncology
Mayo Clinic
2020–2023
Internal Medicine
University of Colorado School of Medicine
2017–2020
Medical College of Wisconsin
2013–2017
University of Minnesota - Twin Cities
2009–2013

Research

Identification and prioritization of myeloid malignancy germline variants in a large cohort of adult patients with AML
Blood · 2022 · 82 citations
Development, expansion, and in vivo monitoring of human NK cells from human embryonic stem cells (hESCs) and and induced pluripotent stem cells (iPSCs)
Journal of Visualized Experiments · 2013 · First of 3 authors · 45 citations
Bacteremia in blood or marrow transplantation patients: clinical risk factors for infection and emerging antibiotic resistance
Biology of Blood and Marrow Transplantation · 2013 · First of 5 authors · 40 citations

GN
Grzegorz Nowakowski
12 papers
Thomas Habermann
7 papers
Yucai Wang
6 papers
Narendranath Epperla
5 papers
RK
Rebecca King
5 papers
Reem Karmali
5 papers
Stephen Ansell
5 papers
Thomas Witzig
5 papers
Umar Farooq
5 papers
Ajay Major
4 papers
BL
Brian Link
4 papers
Kelsey Baron
4 papers

Clinical trials

External Beam Radiotherapy Followed by Bispecific Antibody Therapy for Relapsed/Refractory DLBCL
Site PI · Recruiting · Phase 1
University of Utah
2026–2031
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2024–2032
Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy
Site PI · Recruiting · Phase 2
Academic and Community Cancer Research United
2024–2030
Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM Trial
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2024–2026